CRP and rheumatoid arthritis: After 6 months of GLM treatment for RA, 68% (95% CI: 46.5–85.1%) of patients achieved at least LDA, with 40% (95% CI: 21.1–61.3%) achieving remission, based on DAS28-CRP, while a good/moderate EULAR response was seen in 61.9% (95% CI: 38.4–81.9%).